Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2023 10:05 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
November 15, 2023 09:00 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that...
October 26, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
October 17, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
October 09, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...
August 23, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
August 17, 2023 09:19 ET | Source: ABVC BioPharma, Inc.

ABVC Executes Cooperation Agreement for Strategic Investments

FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
August 10, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

FREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
August 07, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC Corporate Update and CEO's Letter to Shareholders

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
August 03, 2023 09:20 ET | Source: ABVC BioPharma, Inc.

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

FREMONT, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right